United Therapeutics Co. (NASDAQ:UTHR) Shares Purchased by Colonial River Investments LLC

Colonial River Investments LLC boosted its holdings in United Therapeutics Co. (NASDAQ:UTHR) by 12.7% during the fourth quarter, according to its most recent Form 13F filing with the SEC. The fund owned 1,367 shares of the biotechnology company’s stock after acquiring an additional 154 shares during the period. Colonial River Investments LLC’s holdings in United Therapeutics were worth $482,000 at the end of the most recent reporting period.

A number of other large investors have also recently added to or reduced their stakes in UTHR. World Investment Advisors LLC acquired a new position in United Therapeutics in the third quarter valued at approximately $139,206,000. FMR LLC raised its position in United Therapeutics by 41.1% in the third quarter. FMR LLC now owns 1,077,628 shares of the biotechnology company’s stock valued at $386,168,000 after purchasing an additional 314,004 shares during the period. AustralianSuper Pty Ltd raised its position in United Therapeutics by 577.1% in the fourth quarter. AustralianSuper Pty Ltd now owns 189,780 shares of the biotechnology company’s stock valued at $66,962,000 after purchasing an additional 161,751 shares during the period. Assetmark Inc. raised its position in United Therapeutics by 56.9% in the third quarter. Assetmark Inc. now owns 419,957 shares of the biotechnology company’s stock valued at $150,492,000 after purchasing an additional 152,249 shares during the period. Finally, Franklin Resources Inc. raised its position in United Therapeutics by 97.7% in the third quarter. Franklin Resources Inc. now owns 250,719 shares of the biotechnology company’s stock valued at $89,532,000 after purchasing an additional 123,929 shares during the period. 94.08% of the stock is currently owned by institutional investors and hedge funds.

United Therapeutics Trading Down 1.7 %

Shares of UTHR stock opened at $361.10 on Monday. The firm has a fifty day moving average price of $362.68 and a 200 day moving average price of $360.72. The company has a market cap of $16.12 billion, a P/E ratio of 15.86, a PEG ratio of 0.97 and a beta of 0.57. United Therapeutics Co. has a 12 month low of $214.75 and a 12 month high of $417.82.

Insider Buying and Selling

In related news, COO Michael Benkowitz sold 10,000 shares of the business’s stock in a transaction on Monday, February 10th. The shares were sold at an average price of $348.06, for a total transaction of $3,480,600.00. Following the completion of the transaction, the chief operating officer now owns 2,577 shares in the company, valued at approximately $896,950.62. The trade was a 79.51 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, Director Nilda Mesa sold 255 shares of the business’s stock in a transaction on Monday, December 30th. The stock was sold at an average price of $355.77, for a total transaction of $90,721.35. Following the transaction, the director now owns 5,528 shares of the company’s stock, valued at approximately $1,966,696.56. The trade was a 4.41 % decrease in their position. The disclosure for this sale can be found here. Over the last quarter, insiders sold 114,164 shares of company stock worth $41,671,293. Corporate insiders own 11.90% of the company’s stock.

Analysts Set New Price Targets

A number of analysts have issued reports on UTHR shares. StockNews.com raised United Therapeutics from a “buy” rating to a “strong-buy” rating in a research report on Thursday, January 16th. Oppenheimer boosted their target price on United Therapeutics from $575.00 to $600.00 and gave the company an “outperform” rating in a research report on Thursday, October 31st. LADENBURG THALM/SH SH upped their price objective on United Therapeutics from $319.00 to $344.00 and gave the stock a “buy” rating in a research report on Thursday, October 31st. The Goldman Sachs Group upped their price objective on United Therapeutics from $243.00 to $302.00 and gave the stock a “neutral” rating in a research report on Friday, November 1st. Finally, HC Wainwright upped their price objective on United Therapeutics from $400.00 to $425.00 and gave the stock a “buy” rating in a research report on Thursday, October 31st. One analyst has rated the stock with a sell rating, two have assigned a hold rating, nine have given a buy rating and one has given a strong buy rating to the company. According to MarketBeat.com, the company has an average rating of “Moderate Buy” and an average price target of $388.25.

About United Therapeutics

United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients.